SuppreMol obtains license for RA antibody from the University Hospital Regensburg
27-Jul-2012 -
The Bayerische Patentallianz GmbH licences an antibody directed against interleukin 3 (IL-3), which has been generated at the University Hospital Regensburg, to SuppreMol GmbH, a privately held biopharmaceutical company developing innovative therapeutics for the treatment of autoimmune diseases. ...
autoimmune diseases
rheumatoid arthritis